Brian G Atwood
CIK 1266567 · Chief Executive Officer · last filed 2026-01-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TSRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1650
SAN FRANCISCO, CA 94104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (PBAXW) Delisted | Director | 491,784 | $0.05 | $24.6K | $0 | 12 | 2026-01-09 |
| Atreca, Inc. (BCEL) Delisted | Director | 49,654 | $0.15 | $7.4K | $0 | 6 | 2023-06-15 |
| CERO THERAPEUTICS HOLDINGS, INC. (PBAXU) Delisted | Director | — | $10.37 | — | $0 | 1 | 2021-10-12 |
| Clovis Oncology, Inc. (CLVS) Delisted | Director | 58,335 | $0.08 | $4.7K | $0 | 16 | 2021-06-11 |
| LWACU | Director | — | $10.36 | — | $0 | 1 | 2021-01-14 |
| OPGEN INC (OPGN.W) Delisted | Director | 2,050,689 | — | — | $2.48M | 2 | 2016-06-24 |
| VCYT | Director | 3,594,989 | $50.28 | $180.76M | $0 | 3 | 2016-06-20 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Director | 1,092,152 | $38.00 | $41.50M | $1000.0K | 2 | 2015-06-16 |
| INGN | 10%+ Owner | 31,334 | $7.13 | $223.4K | -$1.80M | 3 | 2015-01-06 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | Director | 3,220,948 | — | — | $0 | 10 | 2014-02-21 |
| Trius Therapeutics Inc (TSRX) Delisted | Director | 2,321,310 | — | — | $4.57M | 5 | 2013-05-23 |
| HELICOS BIOSCIENCES CORP (HLCS) Delisted | Director | 10,709,818 | — | — | $1.63M | 6 | 2009-09-21 |
| PHARMION CORP (PHRM) Delisted | Director | — | — | — | $0 | 1 | 2007-06-07 |
Recent Filings · Page 8 of 8
77 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2008-06-13 | HELICOS BIOSCIENCES CORP (HLCS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-03-17 | — | Disp (D) | −15,201 | $0 | |
| 2008-02-22 | CADENCE PHARMACEUTICALS INC (CADX) Delisted | Grant (A) | +1,310,861 | $7.00M | EDGAR |
| 2007-07-31 | HELICOS BIOSCIENCES CORP (HLCS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-06-29 | CADENCE PHARMACEUTICALS INC (CADX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-06-07 | PHARMION CORP (PHRM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-06-01 | HELICOS BIOSCIENCES CORP (HLCS) Delisted | Mixed | +2,135,272 | $1000.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.